Logo for Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Investor Relations Material

Latest events

Logo for Fusion Pharmaceuticals Inc

Study Update

Fusion Pharmaceuticals
Logo for Fusion Pharmaceuticals

Q1 2024

7 May, 2024
Logo for Fusion Pharmaceuticals

Q4 2023

20 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Fusion Pharmaceuticals Inc

Access all reports
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company headquartered in Hamilton, Canada, focusing on the development of radiopharmaceuticals as precision medicines. The company's primary efforts are directed towards developing treatments that utilize alpha particle emitting isotopes to selectively target and destroy tumor cells. Fusion Pharmaceuticals leverages its Targeted Alpha Therapies (TAT) platform, which facilitates the connection of these isotopes to various targeting molecules, aiming to deliver alpha particle payloads directly to tumors. This approach underpins its research and insights into the chemistry and biology of alpha-emitting radiopharmaceuticals, alongside its capabilities in target identification, candidate generation, manufacturing, and supply chain. Its shares are listed on the Nasdaq.